Mephenesin

Summary

Mephenesin (CHEMBL229128) is an approved small molecule (ATC M03BX06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M03BX06
• Chemistry: 182.22 Da · C10H14O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL229128
Name	Mephenesin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4059
ChEBI	CHEBI:94398
ATC	M03BX06
Molecular formula	C10H14O3
Molecular weight	182.22
InChIKey	JWDYCNIAQWPBHD-UHFFFAOYSA-N

SMILES: CC1=CC=CC=C1OCC(CO)O

IUPAC name: 3-(2-methylphenoxy)propane-1,2-diol

ChEBI definition: A glycerol ether in which a single 2-methylphenyl group is attached at position 1 of glycerol via an ether linkage.

Also known as: Decontractyl, Mefenesina, Mephenesin, Mephenesine, NSC-25234, TOLSEROL, mephenesin, SID26748509, MEPHENESIN, SID170466586, SID144204909

Patent coverage: 1,300 distinct patent families (3,150 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,113 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Lysine-specific demethylase 4E.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).